Abstract: A non-aqueous composition is disclosed that includes ascorbic acid, a silicone oil, at least 15% by weight of an essential oil, propylene glycol, and glycerin, wherein at least 50% of the initial amount of ascorbic acid in the non-aqueous composition remains stable when the composition is stored for at least 1 month at room temperature.

Abstract: The present disclosure relates to compositions and methods for treating hair, and for improving the appearance and/or feel of curly hair. The compositions comprise a combination of nanocrystalline cellulose and murumuru butter, and the methods comprise applying the compositions to the hair.

Abstract: A skin care composition comprising low molecular weight acetylated hyaluronic acid or its sodium salt having a weight average molecular weight less than 50 kDa, and a degree of acetylation of at least 3.6 is useful in the treatment of the visible effects of age on human skin.

Abstract: The invention relates to a personal care product for alleviating skin dryness, includes facial skin dryness, breast skin dryness and vulval dryness and for restoring vaginal flora, acidic pH in the vagina, and vaginal health. Embodiments of the personal care product include a formulation including at least about 83 wt. % plant-based glycerides; from about 0.05 wt. % to about 0.15 wt. % sodium hyaluronate; and from about 0.01 wt. % to about 1.5 wt. % sea buckthorn powder. Another embodiment includes a personal care product including at least 55 wt. % plant-based glycerides and from about 20 wt. % to about 42 wt. % sucrose. The personal care product may also include shea olein. The person care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial agent, and synthetic hormone.

Abstract: The present invention relates to a composition for dyeing keratin fibers, in particular human keratin fibers such as hair, comprising one or more oxidation dyes, one or more scleroglucan gums in a total weight content greater than or equal to 0.5% relative to the total weight of the composition, and one or more and optionally one or more additional surfactants, preferably cationic surfactants. The invention also relates to a method for dyeing keratin fibers using said composition and to a multi-compartment device suitable for implementing said composition according to the invention.

Abstract: Provided is a cosmetic having a unique soft and springy feeling in use, capable of stably formulating therein a UV protector, and providing a light feeling in use such that the cosmetic is separated into pieces when applied to the skin. The present invention relates to a cosmetic characterized by comprising (A) a (meth)acrylic acid/an alkyl (meth)acrylate/a (meth)acrylic acid-POE monoalkyl ether ester copolymer, (B) a UV protector, (C) a nonionic surfactant, and (D) a higher alcohol.

Abstract: Disclosed is a cosmetic composition and methods of use, where the composition includes humectant and a copolymer of vinylpyrrolidone and a carboxylic acid monomer in water where (i) the copolymer is present in an amount that is at least about 1% by weight of the total composition, (ii) the humectant is present in an amount that is less than about 10% by weight of the total composition, and (iii) the pH of the water is less than about 5, the copolymer is less than about 10% neutralized, or a combination thereof.

Abstract: A sulphate free cleansing composition for hair and scalp comprising, in an aqueous continuous phase: a total amount of anionic surfactant, amphoteric surfactant and zwitterionic surfactant consisting of: (i) from 3 wt % to 13 wt %, by weight of the total composition at 100% activity, of an alpha olefin sulfonate anionic surfactant of general formula (I): R1—CH?CH—CH2—SO3?M+ (I) in which R1 is selected from linear or branched alkyl groups having from 11 to 13 carbon atoms and mixtures thereof; and M is a solubilizing cation; (ii) from 1 to 6%, by weight of an amphoteric or zwitterionic surfactant, selected from an alkyl betaine of general formula (II) R2—N+(CH3)2—CH2—COO?M+ (II) wherein R2=C12 (Lauryl) or Coco derived; an alkyl hydroxy sultaine of general formula (III), R3—N+(CH3)2—CH2—CH(OH)—CH2—SO3?M+ (III) wherein R3=C12 (Lauryl) or Coco derived; an alkyl aminopropyl hydroxy sultaine of general formula (IV), R4—CO—NH—(CH2)3—N+(CH3)2—CH2—CH(OH)—CH2—SO3?M+ (IV) wherein R4=C12 (Lauryl) or Coco derived; an alky

Abstract: The present invention relates to a composition for treating keratin fibers, preferably hair, comprising: (a) at least one silicone oil in an amount of 20% by weight or more relative to the total weight of the composition; (b) water; and (c) at least one polyol in an amount of 10% by weight or more relative to the total weight of the composition, wherein the ratio of the amount of the (b) water/the amount of the (c) polyol is 3 or less. The composition according to the present invention can also provide keratin fibers such as hair with improved cosmetic effects such as smoothness (e.g.

Abstract: One aspect of the present disclosure relates to a phase transfer cosmetic composition. According to the present disclosure, there can be provided a cosmetic composition which contains a wax having a melting point of 40 to 60° C. and an inulin-based surfactant, wherein the composition maintains a liquid state before applied to the skin and rubbed, and changes to a solid state when applied to the skin, can solve the problems in terms of hygiene and use because it is not used by scooping it by hand, and further, changes its phase to a solid state when applied to the skin and then rubbed, and thus, can solve the problem of dripping when applied to face or skin.

Abstract: The invention relates to a personal care product for alleviating skin dryness, including facial skin dryness, body dryness, and breast skin dryness and for use as a massage oil. Embodiments of the personal care product include a formulation including cocoa butter, kokum butter, shea olein, and hyaluronic acid and/or cannabis oil. The personal care product may also include other plant-based glycerides, natural hormones, herbal roots and oils, amino acids, dietary supplements. The personal care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial, and synthetic hormone.

Abstract: A novel cosmetic complex for bioactive hydration of the skin, particularly from the body and face, is provided. The cosmetic complex comprises vegetable oil, trehalose, and hydroxyethyl urea.

Abstract: The present invention comprises compositions, systems, and methods of improving the skin and the skin microbiome using bacterial strains and their derivatives, and prebiotics. A useful composition of the invention comprises at least one of (a) a prebiotic that selectively promotes the growth of at least one desirable strain of Cutibacterium acnes (C. acnes); (b) a probiotic comprising at least one desirable strain of C. acnes; and (c) a post-biotic comprising at least one molecule produced by C. acnes.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: The present invention relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogel formulations comprising at least one antibiotic for relieving and/or treating low back pain.

Abstract: The present invention relates to thermogelling peptide delivery systems which are injected as fluid sol at ambient temperature through thin injection needles and transform into a highly viscous gel once inserted into human or animal body warm tissue. In a preferred embodiment said system is based on the use of a hydrophobic peptide, a chitosan and a glucose-phosphate.

Abstract: Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application contains budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 12 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application comprises several doses whereby the most preferable dose of budesonide is 2.0 mg per dose. The enema for rectal application is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; has a foamy, more rigid to a more liquid, gel-like structure.

Abstract: A method of delivering drugs to inner ear facilitated by microbubbles, including mixing a microbubble composition and a drug into a microbubble-drug mixture, applying the microbubble-drug mixture to middle ear cavity, and placing a mechanical oscillation wave source to ear canal or cranium located behind the ear. The mechanical waves generated by the mechanical oscillation wave source penetrate through tympanum or cranium, and induce the cavitation on the microbubbles in the middle ear cavity. Thus, the permeability of the round window membrane is increased, so that the drug penetrates into inner through the round window membrane. Therefore, the mechanical oscillation wave source induces the cavitation on the microbubbles in a non-invasive way.

Abstract: The present invention provides aqueous ophthalmic compositions in the form of solution comprising hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester and macrogol 15 hydroxystearate as the only solubilizing agent, and a method for their preparation.

Abstract: Gummy dosage forms comprising gummy compositions for nutritional supplementation, methods for providing nutritional supplementation, and kits comprising gummy compositions for nutritional supplementation are disclosed. Such gummy compositions for nutritional supplementation may provide improved patient compliance relative to non-gummy compositions for nutritional supplementation. These gummy compositions can be used to administer one or more vitamins, minerals, or trace elements.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: The present invention provides a water-based formulation, comprising hydroxypropyl-?-cyclodextrin, an essential oil selected from a group consisting of Eucalyptus Globubus oil and Houttuynia cordata oil, for targeting the respiratory system, in particular for the upper respiratory system. The formulation is delivered as vapors through an inhaler with a controlled heater.

Abstract: Dry powder pharmaceutical compositions for intranasal administration include an opioid receptor antagonist, e.g. naloxone, as active ingredient, and dosage unit forms thereof. Methods of treating opioid overdose include administering the dry powder compositions.

Abstract: Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

Abstract: The present invention provides a preparation for attaching to teeth or tooth peripheries. The preparation for attaching to teeth or tooth peripheries of the present invention can give high adhesive force to the desired site despite interproximal space or curves of teeth. It is easy to hand while controlling drug release.

Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

Abstract: This disclosure provides compositions and methods for improving the dispersion of a hydrophobic amino acid entity in an aqueous suspension. This disclosure further provides compositions and methods for improving the stability of N-acetylcysteine in the presence of acetyl acceptors, e.g., carnitine.

Abstract: A composition in the form of a micro-emulsion composed of an oil phase comprising at least one omega 3 fatty acid or salt thereof and at least one glyceride, an aqueous phase and one or more non ionic surfactant(s), said composition containing at least one creatine fatty ester or salt thereof. Further, a method for preparing such a composition and its use in medicine in particular for treating the brain creatine transporter deficiency disease.

Abstract: The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.

Abstract: The disclosure relates generally to gamma polyglutamated tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated tetrahydrofolate, and methods of making and using the gamma polyglutamated tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

Abstract: An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.

Abstract: The present invention relates to RANKL+ cellular vesicles isolated from osteoblastic lineage cells, optionally immortalised, their use for the therapeutic treatment of bone pathologies and for diagnostic purposes, and processes for the production of said vesicles.

Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Abstract: Methods for manufacturing a non-viral delivery system comprising a liposome encapsulating an RNA using a microfluidic device and compositions for use therein are provided.

Abstract: Provided is an anesthetic composition for locally administering a local anesthetic agent to a subject in need thereof. The anesthetic composition has a lipid based complex prepared by hydrating a lipid cake containing a local anesthetic agent and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more robust for large-scale manufacture and for providing a high molar ratio of local anesthetic agent to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Abstract: The invention discloses a lenalidomide gastro-retentive sustained-release tablet and a preparation method thereof. The sustained-release tablet comprises 3 wt % to 14 wt % of lenalidomide, 14 wt % to 68 wt % of release enhancer with low bulk density, 23 wt % to 70 wt % of sustained-release material with low bulk density, and the balance of other pharmaceutically acceptable excipients, wherein the bulk density of the release enhancer ranges from 0.24 g/cm3 to 0.52 g/cm3; and the bulk density of the sustained-release material ranges from 0.29 g/cm3 to 0.51 g/cm3. The sustained-release tablet of the invention is in a floating state in a gastric environment, is not directly discharged from a stomach due to gastric emptying, has an effect of gastric retention, and is not easily discharged with substances contained in the stomach, and has a high drug bioavailability and small side effects.

Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Abstract: A dosage form of controlled release at specific gastrointestinal sites is provided. The dosage form includes a shell defining a first and a second compartment, a first active pharmaceutical ingredient (API) loaded in the first compartment, and a second API loaded in the second compartment, wherein the first API and the second API can be the same or different. The shell includes a first material soluble in a first gastrointestinal site and a second material soluble in a second gastrointestinal site.

Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

Abstract: The present disclosure belongs to the technical field of soft capsules, and particularly relates to a plant soft capsule and a preparation method and application thereof. The plant soft capsule with excellent performance is prepared from carrageenan, starch, a plasticizer and water by controlling the weight-average molecular weight of the carrageenan to be 1.2×106 to 2.0×106. Compared with a plant soft capsule in the existing technology, the plant soft capsule of the present discourse has lower production cost, and the product quality meets the requirements of gelatin soft capsules; and on the premise of high production efficiency, a low oil leakage rate is achieved, and the rupture time meets United States Pharmacopoeia (USP) standards. The plant soft capsule prepared according to the present disclosure can be filled with an active component as a content and used for preparation of a plurality of drugs, functional food or dietary nutritional supplements.

Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: The disclosure relates to microspheres comprising a core and a shell. More particularly the disclosure relates to microspheres for extended, controlled release of a poorly water-soluble therapeutic agent having a solubility in water of 50 ?g/mL or less, the microsphere having a core comprising the therapeutic agent, and a substantially impermeable shell surrounding the core. Methods of making and using the microspheres are also provided.

Abstract: Treatment protocols based on expression of therapeutic proteins by genetically-modified selected cell types in vivo are described. The treatment protocols can additionally utilize cell attractants to attract selected cell types to a treatment site and/or macrophage activation protocols at the treatment site.

Abstract: A nanoparticle structure is provided. The nanoparticle structure comprises a core comprising first nanoparticles and a shell located on a surface of the core and comprising second nanoparticles. The first nanoparticles may comprise magnetic nanoparticles, and the second nanoparticles may comprise catalytic nanoparticles.

Abstract: Provided are a nanocomposite including a nano-drug delivery system; and a ginseng extract or a ginsenoside isolated therefrom, and a preparation method thereof, in which the nanocomposite may be used for the prevention or treatment of cancer and inflammatory diseases. The metal nanocomposite of the present invention may be prepared in a uniform size without using an additional reducing agent or stabilizing agent in a significantly shortened time, as compared with known metal nanoparticles. Further, since the metal nanocomposite has high solubility in water and high targeting ability for cancer cells, it can be advantageously developed as drugs. Further, the metal nanocomposite exhibits high anti-cancer and anti-inflammatory activities, and thus may be usefully applied to prevention or treatment of cancer and inflammatory diseases.

Abstract: Compounds are provided having the following structure: [Formula should be inserted here] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.